Lakefront Biotherapeutics
In David Einhorn's portfolio · Greenlight Capital
Ticker LKFT
Still in the portfolio as of Q3 2026. Every quarter it shows up in a Greenlight Capital 13F, newest first.
| Quarter | Activity | Shares | Weight |
|---|---|---|---|
| Q3 2026 | No change | 482,746 | 0.4% |
| Q2 2026 | No change | 482,746 | 0.4% |
| Q1 2026 | No change | 482,746 | 0.5% |
| Q4 2025 | No change | 482,746 | 0.6% |
| Q3 2025 | No change | 482,746 | 0.7% |
| Q2 2025 | No change | 482,746 | 0.6% |
| Q1 2025 | Add 1% | 482,746 | 0.6% |
| Q4 2024 | No change | 479,363 | 0.7% |
| Q3 2024 | Add 104% | 479,363 | 0.6% |
| Q2 2024 | Add 47% | 234,828 | 0.3% |
| Q1 2024 | Reduce 2% | 159,828 | 0.2% |
| Q4 2023 | Add 4% | 162,578 | 0.3% |
| Q3 2023 | Add 4% | 156,378 | 0.3% |
| Q2 2023 | Reduce 1% | 150,168 | 0.3% |
| Q1 2023 | Reduce 3% | 151,368 | 0.3% |
| Q4 2022 | Add 6% | 155,358 | 0.5% |
| Q3 2022 | No change | 146,388 | 0.4% |
| Q2 2022 | Reduce 9% | 146,388 | 0.6% |
| Q1 2022 | Reduce 13% | 160,200 | 0.6% |
| Q4 2021 | Buy | 185,000 | 0.6% |
Price is the position's value divided by its shares, at the end of each quarter. Share counts are as filed; when a stock split happened, the change is measured on split-adjusted shares.